Files and links (2)
Published VersionCC BY V4.0, Open Access
Journal article
Metformin, Macrophage Dysfunction and Atherosclerosis
Frontiers in Immunology, Vol.12, pp.1-28
2021
Abstract
Metformin is one of the most widely prescribed hypoglycemic drugs and has the potential to treat many diseases. More and more evidence shows that metformin can regulate the function of macrophages in atherosclerosis, including reducing the differentiation of monocytes and inhibiting the inflammation, oxidative stress, polarization, foam cell formation and apoptosis of macrophages. The mechanisms by which metformin regulates the function of macrophages include AMPK, AMPK independent targets, NF-κB, ABCG5/8, Sirt1, FOXO1/FABP4 and HMGB1. On the basis of summarizing these studies, we further discussed the future research directions of metformin: single-cell RNA sequencing, neutrophil extracellular traps (NETs), epigenetic modification, and metformin-based combination drugs. In short, macrophages play an important role in a variety of diseases, and improving macrophage dysfunction may be an important mechanism for metformin to expand its pleiotropic pharmacological profile. In addition, the combination of metformin with other drugs that improve the function of macrophages (such as SGLT2 inhibitors, statins and IL-1β inhibitors/monoclonal antibodies) may further enhance the pleiotropic therapeutic potential of metformin in conditions such as atherosclerosis, obesity, cancer, dementia and aging.
Details
- Title
- Metformin, Macrophage Dysfunction and Atherosclerosis
- Authors
- Xiaojun Feng (Author) - University of Science and Technology of ChinaWenxu Chen (Author) - University of Science and Technology of ChinaXiayun Ni (Author) - University of Science and Technology of ChinaPeter J Little (Author) - University of the Sunshine Coast, Queensland, School of Health and Behavioural Sciences - LegacySuowen Xu (Author) - University of Science and Technology of ChinaLiqin Tang (Author) - University of Science and Technology of ChinaJianping Weng (Author) - University of Science and Technology of China
- Publication details
- Frontiers in Immunology, Vol.12, pp.1-28
- Publisher
- Frontiers Research Foundation
- Date published
- 2021
- DOI
- 10.3389/fimmu.2021.682853
- ISSN
- 1664-3224
- Copyright note
- Copyright © 2021 Feng, Chen, Ni, Little, Xu, Tang and Weng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
- Organisation Unit
- School of Health; University of the Sunshine Coast, Queensland; School of Health and Behavioural Sciences - Legacy
- Language
- English
- Record Identifier
- 99548404702621
- Output Type
- Journal article
Metrics
22 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Immunology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites